Introduction
Fontan surgery is perceived as having revolutionized the treatment options for patients with complex congenital heart disease in whom a biventricular repair is not possible [1] . However, with increasing time, a number of unpleasant complications have emerged [2] . Protein losing enteropathy (protein loss resulting in hypoalbuminaemia and clinical features including oedema and effusions) is one of the most debilitating and life threatening complications of the Fontan operation, occurring in 3-13% of late survivors [3, 4] and 5-year survival after its onset is only 46% [4] . It is thought to result from the long-term effects on the lymphatic system of the chronically high systemic venous pressure which results from Fontan-type surgery. The protein-losing enteropathy syndrome is likely to represent the extreme end of a spectrum of gastro-intestinal protein loss after Fontan procedures, but whether occult, subclinical protein loss occurs is unknown. This is a study of gastro-intestinal protein loss in adult survivors of congenital heart disease both with and without Fontantype surgery.
Protein loss can be quantified by measuring random faecal 1-antitrypsin, a method shown to be reliable and reproducible [5, 6] . -1-antitrypsin does not undergo proteolysis when leaked into the gut, and since it shares a similar molecular weight with albumin, its loss into the faeces parallels that of albumin. Such protein loss could contribute to the systemic procoagulant state which is common in survivors of the Fontan operation and it is known that the coagulation factors antithrombin III, protein C and protein S may be reduced in post-Fontan patients [7] . Antithrombin III has been measured in this study because of its close structural homology with -1-antitrypsin [8] , and because warfarin therapy does not affect antithrombin III levels.
Methods

Subjects
Protein loss was assessed and related to clinical status in three groups of patients with congenital heart disease. Subjects were recruited from the grown-up congenital heart disease outpatient clinic (of J.S.) and from admission to the GUCH unit ward, Royal Brompton Hospital. The study group contained 20 subjects who had undergone a Fontan type operation or total cavopulmonary connection more than 2 years previously. Results were compared with two age-and sex-matched control groups of patients with congenital heart disease not palliated by Fontan surgery; these groups comprised 14 subjects with normal systemic venous pressure and 14 with chronically raised systemic venous pressure >3 cm. Exclusion criteria were intercurrent infection, gastrointestinal disease, and cardiac surgery within 6 months of the study.
Clinical data
Routine clinical history, examination, echocardiography and blood tests were performed on the same day as stool sample collections. Cardiac catheterization could not be justified in all subjects since most of them were recruited as outpatients, therefore systemic venous pressure in all patients was assessed clinically by the same experienced physician. Data from cardiac catheterization were used in conjunction with clinical assessment of systemic venous pressure in the 15 patients in whom a catheter was performed. Systemic venous pressure measurements during cardiac catheterization were recorded with the subject at rest, fasting, and optimally diuresed, and were frequently lower than the clinical measurements made in the outpatients department. It is therefore the latter clinical measurement which may reflect the subject's true day to day condition most closely. For the control group with elevated systemic venous pressure, chronic elevation was defined as a jugular venous pressure greater than 3 cm above the sternal angle at rest, on two or more consecutive assessments over the preceding year. Twodimensional transthoracic and/or transoesophageal echocardiography or magnetic resonance imaging were used to assess ventricular function, Fontan patency and to detect right atrial thrombus or spontaneous contrast. All patients in the Fontan group had been on long-term warfarin anti-coagulation prior to the study, as is the policy of the unit for such patients.
Protein-losing enteropathy was considered to be present when clinical symptoms of hypoproteinaemia (oedema, effusions, etc) were associated with raised faecal -1-antitrypsin and no evidence of renal protein loss or serious liver dysfunction.
Biochemistry and haematology
Liver function tests and biochemistry were performed by routine analysis using a Beckman CX7 Synchron, and faecal -1-antitrypsin was quantified by immunonephelometry using a Beckman Array Protein Analyser. Antithrombin III was quantified using a chromogenic assay (Boehringer-Mannheim, Mannheim, Germany).
Statistical analysis
Descriptive data are expressed as mean standard deviation. The groups were compared using one way analysis of variance. For the whole study group, the relationship between the dependent variable, faecal -1-antitrypsin and the independent variables of clinical parameters was explored using univariate and multivariate linear regression analysis. Statistical significance was inferred at P<0·05.
Results
Patient characteristics
Details of the basic diagnoses in the Fontan subjects and the type of Fontan surgery performed are shown in Table 1 , and the basic diagnoses in the two control groups are shown in Table 2 . There were no significant differences between the three groups in age, sex or Ability Index, which is a measure of functional capacity [9] (Table 3) . There was significantly greater impairment of ventricular function in the controls with high systemic venous pressure compared to those with normal venous pressure (Table 4 ; P=0·008); there were no other significant differences in ventricular function between the groups. In addition, there was significantly more derangement of hepatic enzymes in the Fontan group and in the control group with high venous pressure than in the group with normal venous pressure ( Table 5) . Within the Fontan group, four patients had evidence at catheter or magnetic resonance imaging of obstruction to their Fontan circuit d3 mmHg; none had clinical protein losing enteropathy. There were no significant differences in systemic venous pressure or faecal -1-antitrypsin between those with and without obstruction.
Faecal -1-antitrypsin measurements
( Fig. 1) Faecal -1-antitrypsin was significantly higher in the Fontan (0·55 0·15 mg . g 1 faeces) and high venous pressure control (0·66 0·30 mg . g 1 faeces) groups than in the normal venous pressure control group (0·29 0·12) (P=0·002 and <0·001, respectively). Nine (45%) of the Fontan subjects, and five (25%) of the subjects with chronic elevation of the systemic venous pressure had faecal -1-antitrypsin levels above normal (>0·5 mg . g 1 faeces), compared with only one of the normal venous pressure control subjects. Of these 15
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subjects with increased gastro-intestinal protein loss, the majority [11] did not have clinical protein-losing enteropathy and hypoalbuminaemia. They differed only from the subjects with normal faecal -1-antitrypsin in having higher systemic venous pressure and serum aspartate transaminase. Univariate analysis revealed a significant direct correlation between jugular venous pressure and faecal -1-antitrypsin (r=0·36, P=0·01) (Fig. 2) . In addition, there was a significant direct correlation between faecal -1-antitrypsin and serum aspartate transaminase (r=0·39, P=0·04). Neither the relationship with venous pressure nor that with aspartate transaminase remained significant on multivariate analysis.
Other clinical parameters: Ability Index [9] , oedema, effusions, ascites, hepatomegaly, atrial arrhythmia, ventricular morphology or function, right atrial thrombus/spontaneous contrast and serum albumin did not correlate significantly with faecal -1-antitrypsin. In addition, within the Fontan group, there were no statistically significant relationships between faecal -1-antitrypsin and age at, or time since Fontan operation, pre-operative pulmonary artery pressure or type of Fontan operation. In particular, total cavopulmonary connection had only been performed on two subjects, 3 and 4 years previously, so no comparison could be made between this operation and classical Fontan surgery. All antithrombin III measurements were within the normal range, and no relationship was found with faecal -1-antitrypsin. Only four patients had clinical protein-losing enteropathy; one of these was in the Fontan group and three were in the control group with elevated systemic venous pressure. These four patients had florid clinical protein-losing enteropathy, with hypoalbuminaemia, hepatomegaly, recurrent effusions and ascites; they all had high faecal -1-antitrypsin (range 0·6-1·3, mean 0·83 mg . g 1 faeces) and impaired ventricular function. One, with a double inlet left ventricle, had had Fontan surgery 20 years earlier aged 18 years. His mean preoperative pulmonary artery pressure was 20 mmHg and he had subsequently had chronic elevation of jugular venous pressure. In the 10 years prior to this study he had suffered recurrent Gram-negative septicaemia secondary to IgM deficiency as well as worsening oedema ascites and effusions. At the time of the study he was Ability Index 4 with a serum albumin of only 17 g . l 1 . He had declined further intervention or surgery and was treated with albumin and immunoglobulin infusions. The other three subjects with protein-losing enteropathy had complex congenital heart disease palliated without Fontan surgery and were Ability Index 2 or 3. Two were awaiting heart transplantation, and one received albumin infusions and was atrioventricularly sequentially paced. Her protein-losing enteropathy resolved. This study did not set out to compare subjects with and without protein-losing enteropathy. Nonetheless, those without protein-losing enteropathy were generally in a better clinical state with higher Ability Indexes, and none were under consideration for cardiac transplantation.
Discussion
Increased protein loss from the gastro-intestinal tract has been found in both Fontan survivors and in the control group with chronically raised systemic venous pressure. Elevated systemic venous pressure correlated [9] . Hepatic enzymes were significantly elevated in the Fontan and high venous pressure control groups compared to those with normal venous pressure. P values are in comparison to the normal venous pressure control group and statistical analysis was by one way analysis of variance. There were no significant differences in liver function tests between the Fontan and high venous pressure groups (data not shown).
1.3
α-1-antitrypsin (mg.g , and in control patients with elevated systemic venous pressure (mean 0·6 mg . g 1 faeces), than in controls whose systemic venous pressure was normal (mean 0·29 mg . g 1 faeces) (P=0·002 and P<0·001, respectively). There was no significant difference in -1-antitrypsin excretion between the Fontan group and the control group with elevated venous pressure. =individuals with protein losing enteropathy.
significantly with increased faecal -1-antitrypsin, further strengthening the hypothesis that by increasing pressure within the intestinal lymphatic system, high systemic venous pressure is an important mechanism in the loss of protein from the intestine. Ventricular function was significantly worse in the controls with high venous pressure, and there was more derangement of liver enzymes in the Fontan and high venous pressure groups in comparison to the control group with normal venous pressure. These factors are likely to be closely linked to the mechanisms and effects of raised systemic venous pressure, and the significant relationship between high aspartate transaminase and faecal -1-antitrypsin is likely to reflect the hepatic congestion resultant from high systemic venous pressure.
The lack of correlation on multivariate analysis between clinical measures and faecal -1-antitrypsin may reflect the small study population, and more work is necessary to explore further the aetiology of occult protein loss. In addition, in this study antithrombin III levels were all normal, but a relationship between a pro-coagulant state and gastro-intestinal protein loss cannot be excluded, since other antithrombotic factors such as protein C and protein S could not be assayed, as all the Fontan survivors were anticoagulated with warfarin.
The adult patients in this quaternary referral centre are a selected population and represent all Fontan patients attending for follow-up to the grown up congenital heart disease clinic and ward for the duration of the study. They are a selected population because they have survived both the early and continuing late attrition of complex congenital heart disease. Many have survived early surgical experience in the Fontan era [10, 11] , and did not have their Fontan surgery as children since they had already reached adulthood when Fontan surgery became widespread. In addition, referrals to a unit such as this may bias the population towards those with more complex anatomical lesions and a higher rate of complications. These factors may partly account for the high rates of intestinal protein loss found in the current study.
The presence of clinical protein-losing enteropathy in only one of the 20 Fontan subjects suggests that protein-losing enteropathy is uncommon in this selected population, even in late survivors. This study also shows that protein-losing enteropathy may occur in patients who have not had Fontan surgery, but who have chronically elevated systemic venous pressure, and it is possible to speculate that it might contribute to the terminal state and rapid decline of patients with longstanding right heart failure. High faecal -1-antitrypsin may pre-date the protein-losing enteropathy syndrome by many years. It is interesting that there are many more subjects with high faecal -1-antitrypsin who do not have protein-losing enteropathy. The significance of this is unknown, but the recognition of increased gastrointestinal protein loss should be followed by investigations to identify Fontan obstruction, intra-atrial thrombus, atrial arrhythmias and ventricular dysfunction. Even in patients with Ability Index 1 or 2 these complications should be treated, either medically or with transcatheter or surgical intervention in order to prevent deterioration in cardiovascular status and the development of protein-losing enteropathy.
In conclusion, this study shows that excessive protein loss from the gut is common and related to high systemic venous pressure in a selected population of long term survivors of the Fontan operation and in other patients with congenital heart disease. The subjects in this study with occult protein loss may represent one end of a spectrum, with those with florid clinical proteinlosing enteropathy at the other. Increased faecal -1-antitrypsin may identify those at later risk of developing clinical protein-losing enteropathy, and might contribute to the oedema and cardiac cachexia described in such patients with chronically high systemic venous pressure. It is therefore proposed that measurement of faecal -1-antitrypsin should be considered in all patients with high systemic venous pressure, as a high faecal -1-antitrypsin may indicate the need for early intervention. S.A.T. is Lecturer in Grown Up Congenital Heart Disease funded by the British Heart Foundation. =Fontan subjects; =controls with high venous pressure; =controls with venous pressure.
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